N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients
暂无分享,去创建一个
L. Kuller | D. Duprez | J. Neaton | R. Tracy | C. Orkin | S. Deeks | Jacqueline Neuhaus | I. Woolley | A. Stoehr
[1] A. Gori,et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure , 2006, Journal of thrombosis and haemostasis : JTH.
[2] K. Anastos,et al. Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. , 2009, AIDS Research and Human Retroviruses.
[3] A. Phillips,et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.
[4] A. Maisel,et al. B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department , 2009, Coronary artery disease.
[5] J. Danesh,et al. B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies , 2009, Circulation.
[6] A. Mocroft,et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients , 2010, AIDS.
[7] A. Jaffe,et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. , 2008, Circulation.
[8] T. Yokoyama,et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. , 2002, Journal of molecular and cellular cardiology.
[9] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[10] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[11] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[12] N. Nikolaou,et al. Brain natriuretic peptide increases in septic patients without severe sepsis or shock. , 2007, European journal of internal medicine.
[13] Pedro Lozano. Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.
[14] G. Mensah,et al. Screening and assessment of coronary heart disease in HIV-infected patients. , 2008, Circulation.
[15] B. Thiers,et al. CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .
[16] B. Hesse,et al. Right and left cardiac function in HIV‐infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: a 5‐year follow‐up study , 2008, HIV medicine.
[17] P. Sax. Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters. , 2010, Circulation.
[18] A. Phillips,et al. Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial , 2008, Antiviral therapy.
[19] C. Latkin,et al. Correlates of Lending Needles/Syringes Among HIV-Seropositive Injection Drug Users , 2007, Journal of acquired immune deficiency syndromes.
[20] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[21] A. Maisel,et al. State-of-the-Art PaperNatriuretic Peptides , 2007 .
[22] R. Erbel,et al. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). , 2005, European journal of medical research.
[23] Jeffrey N. Martin,et al. Impact of HIV Infection on Diastolic Function and Left Ventricular Mass , 2010, Circulation. Heart failure.
[24] J. Struck,et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. , 2008, Journal of applied physiology.
[25] A. D. de Bold,et al. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. , 2004, Journal of molecular and cellular cardiology.
[26] D. Duprez,et al. Untreated HIV Infection and Large and Small Artery Elasticity , 2009, Journal of Acquired Immune Deficiency Syndromes.
[27] H. Sørensen,et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Hang Lee,et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.
[29] C. Katlama,et al. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.
[30] Milton C Weinstein,et al. The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.
[31] G. Lamas,et al. Brain natriuretic peptide and HIV-related cardiomyopathy. , 2002, The AIDS reader.
[32] Y. Pinto,et al. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. , 2008, The American journal of cardiology.